Literature DB >> 20946699

The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors.

Mark J Millan1, Philippe Marin, Maud Kamal, Ralf Jockers, Benjamin Chanrion, Marilyne Labasque, Joël Bockaert, Clotilde Mannoury la Cour.   

Abstract

The novel antidepressant, agomelatine, behaves as an agonist at melatonergic receptors, and as an antagonist at edited, human serotonin2C(VSV) receptors [h5-HT2C(VSV)Rs]. However, its actions at constitutively active 5-HT2CRs have yet to be characterized, an issue addressed herein. At unedited h5-HT2C(INI)Rs expressed in HEK-293 cells, 5-HT enhanced [35S]GTPγS binding to Gαq, whereas the inverse agonists SB206,553 and S32006 inhibited binding and, by analogy to the neutral antagonist, SB242,084, agomelatine exerted no effect alone. Mirroring these observations, 5-HT stimulated, whereas SB206,553 and S32006 inhibited, [3H]inositol phosphate formation. Both the agonist actions of 5-HT and the inverse agonist actions of SB206,553 and S32006 were abolished by agomelatine and SB242,084. As demonstrated by bioluminescence resonance energy transfer, 5-HT enhanced, whereas SB206,553 and S32006 decreased, association of 'h5-HT2C(INI)-Rluc-tagged' receptors with yellow-fluorescence-protein-coupled β-arrestin2. These actions of 5-HT, SB206,553 and S32006 were prevented by agomelatine and SB242,084 were ineffective alone. As shown by ELISA and confocal microscopy, prolonged (18 h) exposure to SB206,553 or S32006 enhanced cell surface expression of N-terminal Flag-tagged h5-HT2C(INI)Rs: these effects were blocked by agomelatine and SB242,084, which were inactive alone. Finally, following pre-exposure to SB206,553 or S32006 for 18 h, 5-HT triggered 5-HT2CR-mediated elevations in cytosolic Ca2+ in primary cultures of mice cortical neurons. Agomelatine and SB242,084, inactive alone, prevented these actions of SB206,553 and S32006. In conclusion, agomelatine behaves as a neutral antagonist at constitutively active h5-HT2C(INI)Rs and native, cortical 5-HT2CRs. It will be of interest to determine whether the neutral antagonist properties of agomelatine are related to its favourable clinical profile of antidepressant properties with few side-effects and no discontinuation syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20946699     DOI: 10.1017/S1461145710001045

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  15 in total

Review 1.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

Review 2.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

Review 3.  Melatonin receptors: molecular pharmacology and signalling in the context of system bias.

Authors:  Erika Cecon; Atsuro Oishi; Ralf Jockers
Journal:  Br J Pharmacol       Date:  2017-08-17       Impact factor: 8.739

4.  Preferential modulation of the lateral habenula activity by serotonin-2A rather than -2C receptors: Electrophysiological and neuroanatomical evidence.

Authors:  Francis Delicata; Cristiano Bombardi; Massimo Pierucci; Roberto Di Maio; Philippe De Deurwaerdère; Giuseppe Di Giovanni
Journal:  CNS Neurosci Ther       Date:  2018-02-25       Impact factor: 5.243

Review 5.  Melatonin in type 2 diabetes mellitus and obesity.

Authors:  Angeliki Karamitri; Ralf Jockers
Journal:  Nat Rev Endocrinol       Date:  2019-02       Impact factor: 43.330

Review 6.  Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.

Authors:  B Guardiola-Lemaitre; C De Bodinat; P Delagrange; M J Millan; C Munoz; E Mocaër
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

7.  Prevention of 5-hydroxytryptamine2C receptor RNA editing and alternate splicing in C57BL/6 mice activates the hypothalamic-pituitary-adrenal axis and alters mood.

Authors:  Vincent Bombail; Wei Qing; Karen E Chapman; Megan C Holmes
Journal:  Eur J Neurosci       Date:  2014-09-26       Impact factor: 3.386

Review 8.  Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders.

Authors:  Moshe Laudon; Anat Frydman-Marom
Journal:  Int J Mol Sci       Date:  2014-09-09       Impact factor: 5.923

9.  Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks.

Authors:  Maximilian Gahr
Journal:  Curr Neuropharmacol       Date:  2014-09       Impact factor: 7.363

Review 10.  Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases.

Authors:  Giuseppe Di Giovanni; Dubravka Svob Strac; Montse Sole; Mercedes Unzeta; Keith F Tipton; Dorotea Mück-Šeler; Irene Bolea; Laura Della Corte; Matea Nikolac Perkovic; Nela Pivac; Ilse J Smolders; Anna Stasiak; Wieslawa A Fogel; Philippe De Deurwaerdère
Journal:  Front Neurosci       Date:  2016-11-24       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.